Epigenomics AG / Key word(s): Contract/DisposalEpigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023 10-Oct-2023 / 20:56 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is […]
Author: mark
10. October 2023
Epigenomics AG: Closing of Agreement on the Acquisition of Almost All Assets and Adjustment of Guidance for 2023
Read more
10. October 2023
Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company’s Assets and Adjustment of Guidance for 2023
EQS-News: Epigenomics AG / Key word(s): Contract/DisposalEpigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of the Company's Assets and Adjustment of Guidance for 2023 10.10.2023 / 21:10 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG Announces Closing of Agreement on the Acquisition of Almost All of […]
11. September 2023
Epigenomics AG: Approval by the Extraordinary General Meeting of the acquisition of almost all assets and corresponding change of the statutory purpose of the Company
Epigenomics AG / Key word(s): AGM/EGMEpigenomics AG: Approval by the Extraordinary General Meeting of the acquisition of almost all assets and corresponding change of the statutory purpose of the Company 11-Sep-2023 / 15:54 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a […]
05. September 2023
Epigenomics AG: Pareto and Warburg publish analyst research reports
EQS-News: Epigenomics AG / Key word(s): Research UpdateEpigenomics AG: Pareto and Warburg publish analyst research reports 05.09.2023 / 17:20 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG: Pareto and Warburg publish analyst research reports Analysts consider acceptance of New Day Diagnostics’ purchase offer advantageous for shareholders Buy recommendation with price […]
10. August 2023
Epigenomics AG publishes financial results for the first six months 2023
EQS-News: Epigenomics AG / Key word(s): Half Year Report/Half Year ResultsEpigenomics AG publishes financial results for the first six months 2023 10.08.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Epigenomics AG publishes financial results for the first six months 2023 Berlin (Germany), August 10, 2023 – Epigenomics AG (FSE: […]
02. August 2023
Epigenomics AG: Capital reduction planned at a ratio of 5 : 1
Epigenomics AG / Key word(s): Corporate Action/MiscellaneousEpigenomics AG: Capital reduction planned at a ratio of 5 : 1 02-Aug-2023 / 10:36 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.The issuer is solely responsible for the content […]